# Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

> **NCT03001323** · NA · TERMINATED · sponsor: **Hennepin Healthcare Research Institute** · enrollment: 27 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Degludec
- **DRUG:** Standard long-acting

## Key facts

- **NCT ID:** NCT03001323
- **Lead sponsor:** Hennepin Healthcare Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2019-01-20
- **Final completion:** 2020-09-25
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Enrollment was too low to provide statistically significant data
- **Last updated:** 2021-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001323, "Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03001323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*